
Preferred Hotels & Resorts Launches the Luxury Travel Report 2025
The Luxury Travel Report by Preferred Hotels & Resorts reveals that today's affluent travelers are investing not just money but meaning into their journeys. Luxury travelers seek immersive, curated experiences that feel personal and enduring— avoiding generic, mass-produced offerings in favor of authenticity and emotional connection.
The Luxury Travel Report identifies The Five Emerging Forces of Luxury Travel, signaling a new era of expectations:
1. The Beige-ification of Travel Is the Industry's Wake-Up Call
Luxury travelers are turning away from sameness in design, service, and experience—nearly 70% say modern luxury hotels have lost their soul to standardization. The rise of 'dupe culture' and algorithm-driven itineraries has fueled a wave of 'destination disillusionment,' where cities and stays feel indistinguishable. Today's affluent traveler craves the unrepeatable: places that excite, environments that surprise, and experiences rooted in individuality. Nearly three-quarters say they won't pay for luxury accommodations that feel generic.
2. Legacy Moments Are the New Luxury Currency
Luxury is less about accumulation – it's about transformation. Today's affluent travelers seek rare, authentic experiences that fundamentally shift their worldview and create lasting memories. Over four-in-five say that insider connections unlock the most unforgettable travel moments and 64% prefer to navigate a destination with advice from locals rather than AI-driven concierge services and digital guides.
3. Curation is the New Standard of Luxury
Curation is now as essential as five-star service. Over 90% of luxury travelers say the best journeys feel effortless yet are expertly crafted, with 89% expressing interest in seeing local charm reflected in hotels. Travel advisors are the new power brokers, with 84% of survey respondents agreeing that a trusted travel advisor is more valuable than unlimited internet research.
4. Heritage Is the New Frontier
Luxury travelers don't want to just observe history – they want to be part of it. Over 90% seek experiences that immerse them in history and culture, favoring heritage-rich stays. Additionally, with 71% planning multi-generational trips in 2025, demand continues to rise for spacious accommodations that foster connection to each other and their own family roots.
5. Loyalty Programs Are Lifelines to Consistency and Customization
Amid economic pressures and rising costs, loyalty has become more valuable than ever. For 82% of luxury travelers, loyalty programs are very important to ensuring hotel quality, while nearly two-thirds say a great past stay drives repeat bookings. Today's loyalty isn't transactional — it's deeply personal, driven by human touch, customization, and consistent excellence.
'The Luxury Travel Report by Preferred Hotels & Resorts deepens our understanding of the ever-evolving desires of luxury travelers, which is a critical step in reinforcing authenticity and spotlighting the unique, curated experiences that can be found throughout our global portfolio,' said Lindsey Ueberroth, Chief Executive Officer of Preferred Hotels & Resorts. 'We are guided by an ethos that celebrates an independent spirit, transformative experiences, and we remain committed to delivering authentic, memorable stays through our 'Believe in Travel' ideology. Through the Report, we hope to inspire meaningful experiences that resonate with the luxury travel set.'
The Luxury Travel Report was conducted by The Harris Poll on behalf of Preferred Hotels & Resorts from February to March, 2025, among over 500 affluent U.S. travelers. Respondents met criteria including an annual household income of more than $250,000, at least $1 million in total assets, and a minimum spend of $10,000 on leisure travel annually.
Explore the full findings of The Luxury Travel Report 2025 at
PreferredHotels.com/TheLuxuryTravelReport
About Preferred Hotels & Resorts
Preferred Hotels & Resorts is the world's largest independent hotel brand, representing more than 600 distinctive hotels, resorts, residences, and unique hotel groups across 80 countries. Through its curated global collections, Preferred Hotels & Resorts connects discerning travelers to the singular luxury hospitality experience that meets their life and style preferences for each occasion. Every property within the portfolio maintains the high-quality standards and unparalleled service levels required by the Preferred Hotels & Resorts Integrated Quality Assurance Program. The I Prefer™ Hotel Rewards program, Preferred Residences℠, Preferred Pride℠, and Preferred Golf™ offer valuable benefits for travelers seeking a unique experience. For more information, visit PreferredHotels.com.
Media Contact: Kate Calciano Coordinator, Public Relations Preferred Hotels & Resorts Office: + 1 646-465-9786 Mobile: +1 929-215-6608 [email protected]

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Upturn
2 hours ago
- Business Upturn
GENIUS Act: The Catalyst for Trillions in Real-World Asset Tokenization with Deal Box and OroBit
San Diego, CA , Aug. 04, 2025 (GLOBE NEWSWIRE) — The passage of the landmark GENIUS Act marks a defining moment for the digital asset industry, further opening the door for mainstream adoption of real-world asset (RWA) tokenization, an industry expected to surpass $16 trillion this decade. Positioned at the heart of this financial evolution are fintech pioneer Thomas Carter's Deal Box and blockchain infrastructure innovator OroBit—two firms uniquely prepared to harness these converging opportunities. The GENIUS Act provides explicit regulatory guidelines for stablecoins and digital assets, clarifying critical elements such as reserve requirements (mandating 100% reserves in USD or short-term Treasuries), monthly audits, AML compliance, and dual federal and state licensing oversight. These clear guidelines remove major uncertainties that have long constrained institutional participation, signaling an era of greater investor confidence and market stability. This regulatory clarity arrives during an unprecedented uptick in institutional interest in cryptocurrency markets, notably driven by recent Bitcoin ETF approvals and increasing investment from banks and asset managers. The crypto market capitalization has surged past $4 trillion, reflecting robust, ongoing confidence from institutional treasuries. Thomas Carter, CEO and founder of Deal Box, emphasized the strategic importance of this regulatory development: 'The GENIUS Act couldn't be better timed. The clarity and legitimacy it provides aligns perfectly with growing institutional confidence in digital assets. This convergence creates precisely the environment we've anticipated, enabling Deal Box and our partners at OroBit to rapidly scale tokenization solutions, especially in private equity and traditionally illiquid markets.' Since its inception in 2016, Deal Box has actively championed the tokenization of private equity and alternative assets, offering investors unprecedented access, transparency, and liquidity. Deal Box is also at the forefront of AI technology, partnering with Wild Mouse, an Australian enterprise software company, which has developed a globally unique platform designed to ingest, analyze, and act on unstructured data at scale, offering transformative potential for companies like OroBit. OroBit complements this vision with their sophisticated Smart Contract Layer (SCL), a robust blockchain protocol built on Bitcoin, securely automating tokenization, ownership management, and compliance processes, providing infrastructure for mainstream adoption. By leveraging Bitcoin—the largest and most secure blockchain—OroBit is strategically positioned to capture substantial value as the Bitcoin network itself experiences historic growth and adoption. Warwick Powell, Chairman of OroBit, highlighted the transformative impact of this legislation and strategic alignment: 'The GENIUS Act directly validates the infrastructure we've developed, clearing the path for institutional-grade adoption at a scale previously unimaginable. Alongside Deal Box, we're positioned to become the new standard-bearer for secure, compliant, and efficient tokenized financial products.' The unified ecosystem they have crafted, powered by an enterprise-grade AI platform, is redefining how private equity, real estate, art, and other high-value assets are owned, traded, and managed globally. The long-anticipated tokenization revolution is now underway. About Deal Box Deal Box is venture capital that fits your life. We bring institutional clarity to tokenized and traditional assets through credible AI structuring, Bitcoin-first token design, and packaging built for investor diligence. Structured for issuer-led offerings under Rule 506(c), Deal Box does not act as a broker-dealer or placement agent and receives no compensation tied to capital raised. contact: [email protected] About OroBit OroBit delivers secure, scalable Bitcoin Layer-2 solutions, enabling sophisticated smart-contract capabilities specifically tailored to institutional and private market asset tokenization. See for more information contact [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash


Business Upturn
2 hours ago
- Business Upturn
CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB
– Biliary tract cancer (BTC) or cholangiocarcinoma is an aggressive tumor with poor prognosis – KUALA LUMPUR, Malaysia, Aug. 04, 2025 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; 'Cyclacel' or the 'Company'), a biopharmaceutical company developing innovative cancer medicines, highlighted a preclinical study from independent investigators titled, ' Evaluation of antitumor effects of plogosertib, PLK1 inhibitor in biliary tract cancer with BUBR1 as a potential biomarker ' in the journal, Cancer Research, previously reported in a poster at the American Association of Cancer Research 2025 annual meeting.1 The investigators found that several BTC cancer cell lines were sensitive to plogosertib both as monotherapy and in combinations. Consistently with its antimitotic mechanism of action, plogosertib promoted mitotic checkpoint complex (MCC) formation in prometaphase, which induced mitotic arrest resulting in apoptosis of BTC cells. The authors have also found that BUBR1, a critical mitotic checkpoint protein, may be useful as a biomarker to assess plogosertib's effectiveness. BTC cells with high BUBR1 expression were found to be more sensitive to plogosertib compared to those with low expression. The study concluded that BTC cells with high BUBR1 expression are sensitive to the PLK1 inhibitor plogosertib that demonstrate synergistic effects when combined with an ATR inhibitor, which suggest that targeting PLK1 could be an effective strategy for BTC treatment, especially with BUBR1 expression as a potential biomarker to inform optimal combination therapies. About Biliary Tract Cancer (BTC) BTC, also called cholangiocarcinoma, is a rare but aggressive cancer occurring in the biliary tract, a network of small tubes, or ducts, connecting the liver, gallbladder and small intestine. According to estimates from the National Cancer Institute's SEER database annual US incidence of BTC is 4.4 per 100,000. Prognosis for BTC patients is poor with 5-year overall survival of approximately 10–40% even after surgical tumor resection. BTC treatment strategies include chemotherapy, surgery, radiation and targeted medicines depending on location and stage. As these approaches are not curative, there is an urgent, unmet medical need to treat patients with relapsed, refractory and/or unresectable BTC. About Polo-like Kinase and Plogosertib Polo-like kinase 1 (PLK1) is a serine/threonine kinase that plays a central role in cell division or mitosis. PLK1 is an important regulator of the DNA damage cell cycle checkpoint, mitotic entry and exit, spindle formation and cytokinesis, or cell separation into daughter cells. In general, cancer cells, and in particular KRAS mutated and p53(-) cells, are very sensitive to PLK1 depletion. In contrast normal cells with intact cell cycle checkpoints are less sensitive. Pharmacological inhibition of PLK1 in cancer cells blocks proliferation by prolonged mitotic arrest and induces onset of apoptotic death of such cells. Plogosertib (formerly CYC140) is a novel, small molecule, selective and potent PLK1 inhibitor. It has demonstrated impressive efficacy in human tumor xenografts at nontoxic doses. Cyclacel's translational biology program supports the development of plogosertib in solid tumors and leukemias. Preclinical data from independent groups have shown that certain ARID1A- and/or SMARCA-mutated cancers, and cancers associated with DNAJ-PKAc fusions, may benefit from treatment with plogosertib. Additionally, recent data suggest that PLK1 inhibition may be effective in KRAS-mutated metastatic colorectal cancer. PLK1 overexpression correlates with poor patient prognosis in several tumors, including biliary tract, esophageal, fibrolamellar liver, gastric, leukemia, lung, ovarian, and squamous cell cancers, as well as MYC-amplified cancers. Initial dose escalation data from a Phase 1 clinical study of oral plogosertib suggest that the compound is well tolerated with no dose limiting toxicity observed in five dosing schedules. Clinical benefit was observed in patients with adenoid cystic, biliary tract, ovarian, and squamous cell sinus cancers. About Cyclacel Pharmaceuticals, Inc. Cyclacel is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle and mitosis biology. The anti-mitotic program is evaluating plogosertib, a PLK1 inhibitor, in patients with both solid tumors and hematological malignancies. Cyclacel's strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications. For additional information, please visit Forward-looking Statements This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended and the Safe Harbor provisions of the US Private Securities Litigation Reform Act of 1995, and encompasses all statements, other than statements of historical fact contained in this press release. These forward-looking statements can be identified by terminology such as 'may,' 'could,' 'will,' 'expects,' 'anticipates,' 'aims,' 'future,' 'intends,' 'plans,' 'believes,' 'estimates,' 'targets,' 'likely to', 'understands' and similar statements. These forward-looking statements are based on management's current expectations. However, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. These statements are neither promises nor guarantees but involve known and unknown risks, uncertainties and other important factors and circumstances that may cause Cyclacel's actual results, performance or achievements to be materially different from its expectations expressed or implied by the forward-looking statements, including conditions in the U.S. capital markets, negative global economic conditions, potential negative developments resulting from epidemics or natural disasters, other negative developments in Cyclacel's business or unfavorable legislative or regulatory developments. We caution you therefore against relying on these forward-looking statements, and we qualify all of our forward-looking statements by these cautionary statements. For a discussion of additional factors that may affect the outcome of such forward-looking statements, see our 2024 annual report on Form 10-K, and in particular the 'Risk Factors' section, as well as the other documents filed with or furnished to the SEC by Cyclacel from time to time. Copies of these filings are available online from the SEC at or on the SEC Filings section of our Investor Relations website at These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. These forward-looking statements should not be relied upon as representing Cyclacel's views as of any date subsequent to the date of this press release. All forward-looking statements in this press release are based on information currently available to Cyclacel, and Cyclacel and its authorized representatives assume no obligation to update these forward-looking statements in light of new information or future events. Accordingly, undue reliance should not be placed upon the forward-looking statements. Contact Cyclacel Pharmaceuticals, Inc. Email: [email protected] © Copyright 2025 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc. SOURCE: Cyclacel Pharmaceuticals, Inc. 1 Yoojin Jeong, Yoojin Jeong, et al, Abstract 5406: Evaluation of antitumor effects of plogosertib, PLK1 inhibitor in biliary tract cancer with BUBR1 as a potential biomarker, Cancer Res (2025) 85 (8 Supplement 1): 5406. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash


Business Upturn
2 hours ago
- Business Upturn
United Rotorcraft Secures First International FIREHAWK® Contract with Colombian Air Force
ENGLEWOOD, CO, Aug. 04, 2025 (GLOBE NEWSWIRE) — United Rotorcraft, a division of Air Methods LLC, is proud to announce its first international contract for the FIREHAWK® helicopter, following a groundbreaking agreement with the Colombian Air Force. This contract marks a significant milestone in the global recognition of the FIREHAWK as a premier aerial firefighting and emergency response asset. Under this agreement, United Rotorcraft will be converting 2 legacy UH-60L Black Hawks to the FIREHAWK configuration. This includes the installation of United Rotorcraft's exclusive high landing gear, a 1,000-gallon DART Aerospace composite belly tank, and an advanced avionics suite designed to improve situational awareness during mission-critical operations. Colombia has a long-standing legacy of leadership in Black Hawk operations. The Colombian Air Force was the first international operator of the Black Hawk and the first to deploy an armed fleet. The Colombian National Police were the first law enforcement agency to operate the Black Hawk. With this new acquisition, the Colombian Air Force becomes the first international operator of the FIREHAWK helicopter. 'Colombia has operated Black Hawk helicopters for 37 years, giving us highly experienced pilots and crewmembers trained specifically for firefighting missions,' said General Luis Carlos Córdoba, Commander of the Colombian Air Force. 'This ensures the successful deployment and operation of the FIREHAWK in our country.' According to official data reported by WRadio on July 11, 2025, more than 7,300 wildfires were recorded in Colombia last year, affecting approximately 290,000 hectares (716,000 acres). 'Wildfires have become a global phenomenon and a growing concern for communities across the world,' said Larry Alexandre, President of United Rotorcraft. 'We are honored to introduce the FIREHAWK's unmatched capabilities to our first international customer and to deliver this life-saving asset to the Colombian Air Force as they strengthen their capacity to protect land, wildlife, and communities from the escalating threat of wildfires. The FIREHAWK has become a benchmark for public agencies across the US Western States, and we are convinced it will become equally popular and effective beyond the US borders, starting with Colombia' This effort was the result of a unique collaboration between the Colombian National Unit for Disaster Risk Management (UNGRD), the Colombian Air Force (FAC), and the Colombian Aeronautical Industry Corporation (CIAC). 'The FIREHAWK is the world's most powerful aerial firefighting platform,' said Carlos Carrillo, Director of UNGRD. 'This technology will enhance emergency response capabilities in moorlands, jungles, savannas, coastal regions, and other hard-to-reach areas.' United Rotorcraft is dedicated to delivering cutting-edge aerial firefighting capabilities through innovation and global collaboration. The introduction of the FIREHAWK into international service represents a major advancement in global wildfire response efforts. ### About United Rotorcraft United Rotorcraft is a leader in mission-critical helicopter completions and modifications, known for designing, manufacturing, and integrating mission-critical equipment for emergency response helicopters. With 30 years of experience in aviation solutions, the company specializes in custom completions for aerial firefighting, search and rescue, and HEMS. Attachment United Rotorcraft Announces First International Contract Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash